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a  b  s  t  r  a  c  t
MicroRNAs  (miRNAs)  are  small  endogenous  RNA  molecules  that  regulate  gene  expression  at  the  post-
transcriptional  level  through  its  sequence  complementation  with  target  mRNAs.  An  individual  miRNA
species  can  simultaneously  inﬂuence  the  expression  of  multiple  genes  and  conversely,  several  miRNAs
can  synchronously  control  expression  of  speciﬁc  gene  product  mRNA  levels.  Thus,  miRNAs  expression
in  cells  has  to  be  precisely  regulated  and  alterations  in miRNA  levels  may  cause  an  aberrant  expres-
sion  of  genes  involved  in  oncogenic  pathways  and  consequently  result  in cancer  development.  Indeed,
miRNA  expression  is often  deregulated  in  many  cancers,  including  B-cell  lymphomas.  Diffuse  large  B-cell
lymphoma  (DLBCL)  is a heterogeneous  group  of  B-cell  lymphomas  with  different  genetic  backgrounds,ymphoma morphologic  features,  and  responses  to  therapy.  Over  the  past  decade,  miRNAs  emerged  as  a  new  tool
for  understanding  DLBCL  biology,  and promising  candidate  molecular  markers  in  DLBCL  classiﬁcation
and  treatment.  In this  review,  we  will  focus  on  miRNAs  aberrantly  expressed  in  DLBCL  and discuss  the
putative  mechanisms  of  this  deregulation.  Additionally,  we  will summarize  miRNAs’  involvement  in the
identiﬁcation  of  DLBCL  subgroups,  and  their  potential  role  as diagnostic/prognostic  biomarkers  as  well
as  speciﬁc  therapeutic  targets  for  DLBCL.© 2013 The Authors. Published by Elsevier Ltd. 
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. Introduction
.1. MicroRNA – biogenesis and function
MicroRNAs (miRNAs) are endogenous short (∼22-nucleotides)
on-protein-coding regulatory RNA molecules. They are synthe-
ized in the nucleus from long primary miRNA (pri-miRNA)
ranscripts and then cleaved by ribonucleases, Drosha and
GCR8/Pasha, to precursor (pre-miRNA) transcripts [1]. Next,
xportin 5 exports the pre-miRNA to the cytoplasm, where pre-
iRNA is further cleaved by ribonuclease Dicer in complex with
RBP and PACT proteins to 22-nucleotide long miRNAs duplex [2,3].
ubsequently, one strand of the duplex is loaded onto Argonaute
Ago) proteins to generate the ribonucleoprotein inhibitory com-
lex (miRISC) and serve as a mature functional miRNA. The other
trand of the duplex was previously believed to be a carrier strand
hat degrades [4–6] however; increased numbers of recent reports
rovide evidence for its expression and functional activity in gene
egulation [7–11]. The miRISC assembly associates with speciﬁc
essenger RNAs (mRNAs) based on its sequence complementa-
ion (“seed region”) in mRNA’s 3′-untranslated regions (3′-UTR),
oding sequences or 5′-untranslated regions (5′-UTR). The asso-
iation of miRNA with mRNA regulates gene expression at the
ost-transcriptional level by either suppressing stability, transla-
ion of the mRNA or both of these processes [12,13].
.2. MicroRNA implication in cancer
Since the discovery of the ﬁrst miRNA, lin-4, in nematode worms
n 1993 [14,15], miRNAs have been assessed to regulate nearly 60%
f protein-coding mammalian genes [16,17], and this number will
ost certainly increase with the future research. Single miRNA
an usually simultaneously control different target mRNAs and
onsequently inﬂuence production of multiple proteins [18–20].
onversely, multiple miRNAs can often synchronously target the
ame mRNA and jointly control expression of the particular gene
roduct [21–23]. Recent data from miRNA-based high-throughput
unctional screens revealed that miRNAs have the potential to
egulate multiple functionally related genes involved in a spe-
iﬁc biological pathway [24], reviewed in [25]. The cooperative
iRNA interactions with the target mRNAs can inﬂuence a vari-
ty of critical biological programs such as cell division, apoptosis,
ifferentiation, development, senescence, metabolism, control of
ematopoiesis and tumorigenesis [26,27]. In fact, the regulation
f whole biological pathways is the result of not only direct
iRNAs–mRNAs interactions but also indirect effects through
iRNAs-mediated alteration of components of transcription, trans-
ation or RNAi systems [20]. This extensive deregulation of miRNA
xpression may  result in the activation of several oncogenic path-
ays and subsequently lead to cancer development. Indeed, gene
xpression proﬁling studies and bioinformatic analysis have dis-
overed that cancer cells retain speciﬁc miRNA signatures different
rom those of normal cells [28–31]. Interestingly, the majority
f human miRNAs genes are located at the genomic loci fre-
uently implicated in cancers, called cancer-associated genomic
egions (CAGRs) [32,33]. Many reports have described miRNAs
hat function exclusively as either oncogenes or tumor suppres-
ors. However, a number of miRNAs have also been shown to play
oth oncogenic or tumor-suppressor function in distinct types of
ancer [27,34], reviewed in [35,36]. Recognition of miRNA par-
icipation in cancer pathogenesis has prompted investigators in
he development of preclinical studies targeting speciﬁc miR-
As. Consequently, numerous miRNAs have become candidates for
iagnostic and prognostic biomarkers and targets for cancer ther-
peutic intervention [37–40], including hematologic malignancies
29,30,41–47]. Recent investigations have established miRNAs asemia Research 37 (2013) 1420– 1428 1421
predictive of chemo- and radiosensitivity in cancer as well as miR-
NAs’ efﬁcacy in resensitizing resistant cancer cells [48–51].
1.3.  Diffuse Large B-cell Lymphoma (DLBCL)
Diffuse Large B-cell Lymphoma (DLBCL) is the most common
form of non-Hodgkin lymphoma (NHL) in the adult population,
representing approximately 30–40% of all NHLs, and accounting
for more than 80% cases of aggressive lymphomas in the world
[52]. DLBCL is highly heterogeneous group of B-cell lymphomas
with different genetic abnormalities, molecular grounds, clini-
cal characteristics, therapy responses, and prognosis [53]. Based
on gene expression proﬁling and immunohistochemical studies,
DLBCL has been classiﬁed into three major molecular subtypes:
germinal center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC)
DLBCL and primary mediastinal large B-cell lymphoma (PML-
BCL) [53–57]. GCB-DLBCL has frequent BCL2 translocations, REL
ampliﬁcations, and somatic hypermutation of the immunoglobu-
lin genes [55]. Both ABC-DLBCL and PMBCL are characterized by
constitutively activated NF-B signaling with the more aggres-
sive ABC-DLBCL having a poorer clinical prognosis [54,55]. The
Rituxin-CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Pred-
nisolone) immuno-chemotherapy regimen is the standard therapy
used for the treatment of DLBCL. Unfortunately a large number
of DLBCL patients ultimately develop refractory disease [58–60]
and the precise mechanism underlying DLBCL drug resistance has
not yet been determined. Although recent advances in combined
therapy improved overall survival rates [58,61–64], the response
to treatment remains variable and a heterogenic nature of DLBCL
adds additional complexity in the treatment of the disease. As a
consequence, a substantial proportion of DLBCL patients remain
uncured and the identiﬁcation of appropriate second-line therapies
for them is challenging. Hence, better understanding of lymphoma
biology, identiﬁcation of additional biologic markers that can accu-
rately predict survival and novel molecular targets is crucial for the
improvement of the current diagnostic and treatment tools, and
clinical outcome of patients with DLBCL (reviewed in [53]).
In  the last few years miRNAs have provided a new platform for
the understanding of DLBCL biology and emerging candidates for
both predictive and prognostic biomarkers in DLBCL. miRNA signa-
tures may  provide information for speciﬁc tumor drug resistance or
sensitivity and clinical outcome in chemo-immunotherapy-treated
DLBCL  patients [50,51]. The deﬁnitive proof for direct miRNA con-
tribution to initiation and progression of B-cell lymphoma has
been established by the generation of animal models in which
modulation of miRNA levels directly impacts B-cell lymphoma
development. In this review we  will summarize the literature on
miRNAs that have been implicated in B-cell lymphoma, with a spe-
cial focus on DLBCL. We  will discuss the deregulation of miRNAs
in DLBCL, its implication in the identiﬁcation of DLBCL subgroups
and potential as diagnostic and prognostic biomarkers as well as
speciﬁc therapeutic targets for DLBCL.
2. miRNA signature in DLBCL diagnosis and classiﬁcation
In  light of miRNAs’ potential as diagnostic markers for can-
cer prognostication there is increasing interest in the possible
role for miRNAs as markers for both B-cell differentiation stage
and malignant transformation. It has been shown that miRNA
expression patterns can characterize stages of human B-cell differ-
entiation [29,30,65,66], reviewed in [67]. To date, a large number
of microRNA signatures characterizing lymphomas were identi-
ﬁed, and the role of miRNAs in the development, classiﬁcation
and in the regulation of target genes is under intensive investi-
gation [30,42,68]. Here, we  discuss in detail four of the miRNAs
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eregulated in DLBCL (miR-17-92, miR-155, miR-21 and miR-34a)
hich are among the best studied owing to the availability of both
ain and loss of function in mouse models.
.1. miR-17-92 cluster
The  ﬁrst study to discover that miRNAs could affect lymphoma-
enesis appeared in 2004 when a novel gene, C13orf25, was
dentiﬁed to be upregulated in B-cell lymphoma cell lines and
LBCL patients with 13q31-q32 ampliﬁcations [69]; subsequent
nvestigation discovered that C13orf25 contains the miR-17-92
olycistron encoding six, processed from the same precursor,
iRNAs (miR-17-5p, miR-18, miR-19a, miR-19b, miR-20a and
iR-92-1) [34,69]. The aberrant overexpression of the miR-17-92
olycistron in B-cell lymphomas suggested its oncogenic poten-
ial. Functional evidence for mir-17-92 tumorigenic activity came
rom a mouse B-cell lymphoma model, in which virus-mediated
onstitutive overexpression of mir-17-19b (a truncated mir-17-92
acking mir-92) in coordination with the c-myc oncogene, acceler-
ted B-cell lymphomagenesis and progression [34]. Remarkably,
ice overexpressing miR-17-92 in wild type lymphocytes also
eveloped lymphoproliferative disease, autoimmunity and died
rematurely but did not developed lymphoma [70]. Lymphocytes
rom these mice exhibited reduced expression of miR-17-92 tar-
ets, the pro-apoptotic PTEN and Bim. These and other data suggest
hat Myc  and the miR-17-92 cluster synergistically contribute to
ggressive cancer development mainly by repressing tumor sup-
ressor genes [71]. Ventura and colleagues by demonstrating that
ermline deletion of miR-17-92 cluster inhibits the pro-B to pre-B
ransition conﬁrmed that miR-17-92 is a major participant in B-cell
ifferentiation [72]. An additional report showed that deletion of
he complete miR-17-92 cluster slows Myc-induced oncogenesis
73]. Furthermore, modulation of levels of individual member-
iRNAs from miR-17-92 polycistron in a E-myc B-cell lymphoma
ice model revealed that miR-19 is a key component for the onco-
enic activities of the whole miR-17-92 cluster [73,74]. Lenz and
oworkers found that frequent ampliﬁcation of the oncogenic mir-
7-92 cluster was connected to deletion of the tumor suppressor
TEN in GCB type DLBCL but not in ABC like DLBCL [75]. More-
ver, miR-17-92 microRNA cluster members were found to be
pregulated in GC-DLBCL in comparison with high-grade follicu-
ar lymphoma (FL) [76]. Gene expression analysis of lymphoma
ell lines transfected with miR-17-92 suggests the miR-17-92 poly-
istron regulates distinct targets in different B-cell lymphoma
ubtypes [77]. Although further studies are needed to investigate
he role of miR-17-92 in DLBCL, existing reports show that the
iR-17-92 cluster plays a crucial role in B cell development and
roliferation, and may  be considered as a diagnostic tool to differ-
ntiate large B-cell lymphoid neoplasms.
.2. miR-155
Encoded by BIC, miR-155 has been demonstrated to func-
ion in hematopoiesis and the immune response [78–80], acting
s an oncogenic miRNA (oncomiR) in many malignancies, espe-
ially B-cell lymphoproliferative disorders. On the physiological
evel, miR-155 was shown to play a critical role in B-cell matu-
ation and lymphocyte activation (reviewed in [80]). miR-155 has
een found overexpressed in several lymphomas, including DLBCL
44,68,81–83]. Upregulation of miR-155 was shown to overex-
ress SH2-domain containing inositol-5-phosphatase-1 (SHIP-1),
hich subsequently activates the AKT pathway, inducing B-cell
roliferation [84,85]. Further studies exploring the regulatory func-
ions of miR-155 in DLBCLs demonstrated that miR-155 represses
HIP1 levels in TNF--dependent manner [86,87]. miR-155 was
lso found to regulate expression of activation-induced cytidineemia Research 37 (2013) 1420– 1428
deaminase  (AID), a major DNA mutator in GCB cells [88,89]. Recent
studies demonstrated that BCL6 transcriptionally modulates miR-
155 and consequently inﬂuences expression of AID and other genes
relevant for the GC phenotype [90]. Furthermore, DLBCL cell lines
and primary samples exhibit positive correlation between miR-155
upregulation and NF-B activation [91,92]. Importantly, higher lev-
els of mir-155 were discovered in ABC [30,42–44,81–83,91] and
PMBCL [81] phenotypes when compare to GCB type of DLBCL. Dif-
ferential miR-155 expression in subtypes of DLBCL can therefore
serve as a valuable marker for DLBCL diagnosis and prognosti-
cation. In vivo research demonstrated that ectopic expression of
miR-155 in a transgenic mouse model results in B-cell malig-
nancy [84,93]. Recent results obtained from a mouse xenograft
model for anti-miR-155-mediated inhibition of miR-155 in low-
grade B-cell lymphomas emphasize the potential of therapeutic
targeting of miR-155 in lymphoma malignancies [94]. In sum-
mary, despite a large body of evidence supporting the therapeutic
potential of targeting miR-155, the exact mechanism by which it
promotes transformation is not yet fully understood and appears
to involve several different targets and pathways. Therefore, tar-
geted miR-155 inhibition in the treatment of DLBCL and other B-cell
malignancies is an area of active investigation.
2.3. miR-21
Another miRNA, which has been validated to play a major role
in lymphomagenesis is miR-21. An oncogenic function for miR-
21 has been supported by elevated miR-21 expression in most
tumor types including B-cell malignancies [42,44,95,96]. Medina
and colleagues established strong evidence for the role of miR-21
in cancer by employing an in vivo model of miRNA-21-induced
pre-B-cell lymphoma; utilizing Cre and Tet-off technologies the
authors generated a mouse model of conditional and inducible miR-
21 expression. In this model, elevation of miR-21 levels caused
pre-B malignant lymphoid-like phenotype, and miR-21 inactiva-
tion completely regressed tumors via apoptosis and cell arrest [96].
These data not only reinforced a strong oncogenic role of miR-
21 but also demonstrated the ﬁrst case of tumor addiction to an
oncomiR. Microarray analysis identiﬁed elevated levels of miR-21
to be associated with ABC-type compared to GCB-type DLBCL cell
lines [30,42–44]. A recent study demonstrated that miR-21 knock-
down could signiﬁcantly increase DLBCL cell sensitivity to the CHOP
chemotherapy regimen, supporting the importance of this miRNA
for DLBCL drug resistance [60]. Although further studies are neces-
sary for validation, the previous work provides support for miR-21
as a potential DLBCL therapeutic target.
2.4. miR-34
In  contrast to the miRNAs presented above, miR-34a has been
shown to be repressed in diffuse large B-cell lymphoma (DLBCL)
cells and has emerged as a potent tumor suppressor [97,98]. miR-
34a is a member of the miR-34 family in which alteration has been
described in many type of cancers (reviewed in [99]). A number
of reports revealed that the gene encoding miR-34a is transcrip-
tionally regulated by the tumor suppressor p53 [100–102]. Rao
and colleagues found that constitutive overexpression of miR-34a
causes a partial inhibition in B cell development, while its silencing
increased the numbers of mature B cells [103]. These ﬁndings sug-
gest that, similar to the miR-17-92 cluster, miR-34a is important for
B cell proliferation and development. Therapeutic beneﬁt of miR-
34a modulation was demonstrated in vivo, in a xenograft mouse
model of DLBCL, in which the systemic administration of miR-
34a suppressed growth of DLBCL via its pro-apoptotic properties
[98]. Further investigation of the mechanistic basis underlying miR-
34a tumor-suppressor activity showed, that miR-34a suppresses
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Table  1
MicroRNAs deregulated in DLBCL.
miRNA name Expression in DLBCL Comparison cell type References
miR-9 High Normal lymphocytes [43,44]
BL  [106]
miR-17-5p  High Non-neoplastic LN, FL [68]
Normal B-cells [34,42]
Normal lymphocytes [43]
miR-18a  High Normal tonsillar lymphocyte [30]
Normal lymphocytes [43]
miR-18b  High Non-transforming FL [44]
Normal B-cells [42]
Normal lymphocytes [43]
miR-19a  High Normal B-cells [34]
miR-19b  High Non-transforming FL [44]
Normal B-cells [34,42]
miR-20  High Normal B-cells [34,42]
miR-20a  High Non-transforming FL [44]
Normal tonsillar lymphocytes [30]
Normal lymphocytes [43]
miR-21  High Normal lymphocytes [44]
Serum  from healthy patients [126]
miR-93  High Non-transforming FL [44]
Normal tonsillar lymphocyte [30]
Normal B-cells [42]
miR-100  High Normal lymphocytes, non-transforming FL [44]
miR-106a  High Non-neoplastic LN [68]
Non-transforming FL [44]
Normal  tonsillar lymphocytes [30]
Normal B-cells [34,42]
miR-106b  High Normal tonsillar lymphocyte [30]
Normal B-cells [42]
miR-143  High Normal lymphocytes [44]
miR-146a  High BL [106,107]
Reactive lymphoid nodes [83]
miR-155  High Non-neoplastic LN [68]
Normal lymphocytes [44,81]
BL  [106,107]
Serum from healthy patients [126,127]
Reactive lymphoid nodes [83]
miR-182  High BL [106]
Normal lymphocytes [43]
miR-210  High Non-neoplastic LN [68]
Serum from healthy patients [126]




miR-15a,  miR-16-1 High Serum from healthy patients [127]
miR-7,  miR-33, miR-105a, miR-183 High Normal lymphocytes [43]
miR-34b,  miR-146b, miR-221, miR-365 High BL [106,107]
miR-15b,  miR-16, miR-17, miR-18, miR-146 High Normal B-cells [42]
miR-30a,  miR-30d, miR-103, miR-107, miR-142-5p, miR-222,
miR-342-3p
High  BL [107]
miR-17,  miR-25, miR-92a, miR-128a, miR-130b, miR-181b, miR-425 High Normal tonsillar lymphocyte [30]
miR-30b,  miR-98, miR-126*, miR-191, miR-196b, miR-199a*, miR-374,
miR-582, miR-660
High  BL [106]
miR-10b,  miR-22, miR-24, miR-199a, miR-199b, miR-200c, miR-206,
miR-362,  miR-518a, miR-636, miR-638
High Non-transforming FL [44]
let-7e  Low Non-neoplastic LN [68]
Normal B-cells [34]
let-7i  Low Normal CD19+ B-cells [105]
miR-34a  Low - [94]
Serum from healthy patients [127]
miR-150  Low Non-neoplastic LN, FL [68]




miR-320  Low Non-neoplastic LN [68]
Normal tonsillar lymphocyte [30]
miR-328  Low Non-neoplastic LN [68]
BL  [106,107]
miR-485-3p  Low BL [106,107]
let-7d,  let-7g Low Normal CD19+ B-cells [105]
Normal B-cells [34]
miR-24,  miR-101 Low Normal tonsillar lymphocyte [30]
miR-487b,  miR-92b Low FL [105]
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miRNA name Expression in DLBCL Comparison cell type References
let-7a, let-7b, let-7c Low Normal B-cells [34]
miR-10a,  miR-139, miR-149, miR-151 Low Non-neoplastic LN [68]
miR-154,  miR-342, miR-405, miR-708-3p Low Normal lymphocytes [43]
miR-213,  miR-126, miR-135a, miR-330, miR-338 Low FL [68]
miR-181a,  miR-189, miR-217, miR-361, miR-363, miR-584, miR-625,
miR-634, miR-768-5p
Low Normal lymphocytes [43,44]
miR-197,  miR-453, miR-483, miR-516-3p, miR-520c, miR-520d,
miR-520f,  miR-560, miR-573, miR-574, miR-595, miR-609, miR-615,
miR-629, miR-663
Low BL [106]
miR-26a-1*,  miR-26b*, miR-93*, miR-105*, miR-124, miR-185,
miR-192,  miR-193a-5p, miR-202*, miR-326, miR-339-5p, miR-340,
miR-371-5p, miR-429, miR-448, miR-483-3p, miR-497
Low  BL [107]
let-7f  High BL [106]
Low Normal B-cells [34]
miR-9*  High BL [106]
Low BL [107]
miR-17-3p  High Normal B-cells [34]
Low BL [106]
miR-20b  High Normal tonsillar lymphocytes [30]
Normal lymphocytes [43]
Low FL [105]
miR-26a  High BL [107]
Low FL, normal CD19+ B-cells [105]
Normal lymphocytes [43]
miR-26b  High BL [106,107]
Low Non-transforming FL [44]
miR-29b High BL [106,107]
Low Normal tonsillar lymphocyte [30]
miR-29c  High Serum from healthy patients [127]
Low Normal tonsillar lymphocyte [30]
miR-92  High FL [68]
Non-transforming FL [44]
Low Normal B-cells [34]
BL [106]
miR-95  High Normal lymphocytes [43]
Low Non-neoplastic LN [68]
miR-99a  High Non-transforming FL [44]
Low Non-neoplastic LN [68]
miR-125b  High Normal lymphocytes [44]
BL [106]
Low FL [68]
miR-145  High Normal lymphocytes [44]
Low Non-neoplastic LN [68]
miR-223  High BL [106]
Low Normal lymphocytes [43,44]
miR-301  High Normal lymphocytes [44]
Low FL [68]
miR-324-5p  High Normal lymphocytes [43]
Low BL [107]
miR-23a,  miR-23b High BL [107]
Low Normal tonsillar lymphocyte [30]
















(bbreviations: DLBCL, diffuse large B-cell lymphoma; BL, Burkitt’s lymphoma; FL, f
rowth of DLBCL, primarily through targeted repression of tran-
cription factor FoxP1 [97,98,103], a hematopoietic oncoprotein
nd prognostic marker in DLBCL patients [104]. Details of the
nderlying mechanisms behind miR-34a pro-apoptotic effects are
ctively being investigated.
.5.  Other miRNAs aberrantly expressed in DLBCL
In addition to the miRNAs described above, which have been
xperimentally veriﬁed in pre-clinical animal models, a number
f miRNA proﬁling assays performed in lymphoma patient sam-
les have identiﬁed other candidate microRNAs putatively involved
n DLBCL pathogenesis (Table 1). Because of the heterogeneous
ature of DLBCL, in recent years studies have attempted to dis-
inguish DLBCL from other lymphoma types while also ﬁnding
peciﬁc miRNAs differentially expressed between DLBCL subtypes
Table 2). Comparison of miRNA proﬁles in reactive lymph nodes, Normal tonsillar lymphocyte [30]
ar lymphoma; LN, lymph nodes.
DLBCL  and follicular lymphoma (FL) revealed four miRNAs (miRs-
210, -155, -106a and -17-5p) signiﬁcantly highly expressed, and
11 repressed (miRs-150, -145, -328, -139, -99a, -10a, -95, -149, -
320, -151, -let 7e) in DLBCL when compared to normal tissue [68].
The same analysis revealed, eight miRNAs (miRs-21, -19a, -23a, -
27a, -127, -34a, -195, -let 7g) correlating with survival in DLBCL
and four miRNAs (miRs-330, -17-5p, -106a, -210) separating DLBCL
and FL cases. By using a microarray approach, Lawrie and cowork-
ers obtained distinct miRNA expression patterns between DLBCL
and FL. These speciﬁc microRNA signatures were able correctly pre-
dict lymphoma type in 95% of cases [44]. Other microarray analysis
in B-cell lymphoma cell lines identiﬁed discriminatory microRNA
signatures between DLBCL vs. FL and lymphoma against normal
CD19+ PB B-cells [105]. Recent studies by Di Lisio and colleagues
have identiﬁed a signature of 128 speciﬁc miRNAs, which enable
the characterization of different B-cell lymphoma types [106]. In
this work, comparative microarray analysis data were validated
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bbreviations: GCB, germinal center B-cell; ABC, activated B-cell.
y parafﬁn-embedded samples for 19 miRNAs discriminating BL
nd DLBCL (miRs -155, -29b, -146a, -17-3p, -365, -30b, -595, -
63, -573, -26b, -374, -520d, -92, -let7f, -516-3p, -9, -629, -9*,
34b). Lenze and coworkers, by microarray proﬁling of patient sam-
les, identiﬁed 38 MYC  regulated and NF-B pathway-associated
iRNAs, which were differentially expressed between DLBCL and
urkitt lymphoma (BL) [107]. Five of the miRNAs (miRs-155, -221,
222, -146a and -146b) found in this study to be upregulated in
LBCL compare to BL, have also been reported among other dis-
overed unique miRNAs for the two main DLBCL classes. These ﬁve
iRNAs distinguished the GCB–DLBCL type from ABC–DLBCL by
eing upregulated in ABC type [30,42,44,51,91]. Montes-Moreno
nd coworkers found miR-144 and miR-451 to be elevated in
BC type and conversely miR-331, miR-151, miR-28, and miR-
54-3p were upregulated in the GC-type DLBCL [51]. Culpin and
olleagues, using microRNA proﬁling technology and a number
f B-cell lymphoma cell lines, identiﬁed an additional nine miR-
As that separated ABC- and GC-type DLBCL [105]. Together, these
eports conﬁrm that differences in the expression of speciﬁc miR-
As can be considered as a potential indicator to deﬁne DLBCL
ubtypes.
. Mechanisms involved in miRNAs deregulation in DLBCL
Since  an individual miRNA species can inﬂuence the expression
f multiple genes, miRNA levels in cells have to be precisely regu-
ated. As we described above, an alteration in miRNA levels causes
n aberrant expression of miRNA target genes and consequent dis-
uption of the gene expression proﬁle, which can result in cancer
evelopment. Studies have identiﬁed multiple mechanisms that
ontribute to the modulations of miRNA expression levels. These
lterations can originate from several reasons; the most thoroughly
tudied are genomic mutation of miRNA loci, epigenetic changes
nd deregulation of transcription factors (reviewed in [108]).Deletions  at 13q14.3 are present in both chronic lymphocytic
eukemia (CLL) and DLBCL cases [109]. Located at 13q14, miR-
5a and miR-16a, are often deleted or repressed in B-cell chronic
ymphocytic leukemia [110]. However, no reduced miR-15a andemia Research 37 (2013) 1420– 1428 1425
miR-16a  expression was  found in DLBCL cases [111,112]. Translo-
cation at t(3;7)(q27;q32) in DLBCL was shown to fuse BCL6 to a
noncoding region of FRA7H near miR-29 and down-regulate the
levels of miR-29 [113]. Genome-wide miRNA proﬁling revealed a
mutation in the seed sequence of miR-142 in approximately 20% of
DLBCL patients [114]. Additional studies, suggest that loss of tumor-
suppressive function of miR-142 may  contribute to cell growth
stimulation and induction of DLBCL [115].
Another mechanism that has recently emerged in the regulation
of miRNAs expression is epigenetics. Speciﬁcally, DNA hyper-
methylation of microRNA gene promoters has been found to be
responsible for miRNAs repression in cancers. In this topic, tumor
suppressor miRNAs such as miR-203, miR-124-1, miR-34a and miR-
129-2 are frequently silenced by hypermethylation in many cases
of hematologic malignancies including NHLs and were suggested
to corroborate in lymphomagenesis [116–119].
Like other genes, miRNAs expression can also be regu-
lated by conventional transcription factors. The most extensively
investigated is c-Myc, a transcription factor that is frequently dis-
rupted in different types of lymphoma. O’Donnell and colleagues
demonstrated that c-Myc speciﬁcally targets and upregulates the
miR-17-92 cluster [120]. Extensive miRNA microarray analysis
has identiﬁed large set of c-Myc-regulated miRNAs in aggres-
sive B-cell malignancies including miR-34a and miR-15a/miR-16-1
[97,121,122].
Besides the widely investigated mechanisms described above,
the other causes may  add further complexity for understanding
the loss or gain of miRNAs in cancers. In particular, miRNAs dere-
gulation in B-cell lymphoma may  be additionally complicated by
Epstein–Barr virus (EBV) infections, which are found in around
15% of DLBCL cases. EBV encoded miRNAs were found to be active
players in the lymphoma pathogenesis by employing the cellular
miRNAs to modulate cellular miRNAs levels and subsequently the
expression of target genes in infected DLBCL [114,123]. Overall, a
growing body of evidence suggests that aberrant expression of a
single miRNA is the result of a variety of deregulating mechanisms,
which altogether account for changes in miRNA levels (reviewed in
[124]).
4. miRNAs as biomarkers in prognosis and treatment of
DLBCL
Discovery  of extracellular miRNAs in body ﬂuids has raised the
possibility of utilizing levels and composition of circulating miRNAs
as novel non-invasive biomarkers for identiﬁcation of malignant
and non-malignant diseases [125]. Lawrie and colleagues were the
ﬁrst to investigate circulating miRNAs in DLBCL [126]. They found
increased levels of DLBCL-associated miRNAs-155, miRNA-210 and
miRNA-21 in serum DLBCL when compared with healthy controls
patients. They also found that high levels of miR-21 in the serum
of DLBCL patients were associated with an increased relapse-free
survival. Recently published by Fang and coworkers, examination
of miRNAs in serum samples from patients with DLBCL and healthy
controls found signiﬁcantly elevated miR-15a, miR-16-1, miR-29c
and miR-155, while lowered miR-34a in DLBCL when compared
with normal controls, suggesting circulating miRNAs as potentially
useful tools for diagnosis of DLBCL [127]. So far, circulating miR-
NAs is an intense area of investigation and a growing numbers of
studies continue to discover the importance of circulating miRNAs
in cancer and other diseases.
An increasing body of evidence links miRNAs levels with
chemotherapy drug resistance in tumor cells. Recent data have
shown that expression of miRNAs may  indicate sensitivity or
resistance to speciﬁc drugs in B-cell NHL lymphoma treatment
and correlate with clinical outcome of uniformly treated DLBCL








































R426 K. Mazan-Mamczarz, R.B. Gartenhaus
atients. For example, studies by Montes-Moreno and colleagues
dentiﬁed a set of miRNAs associated with prognosis in immuno-
hemotherapy treated DLBCL patients [51]. These and several other
nvestigations found a relationship between miR-222, miR-181a,
iR-18a expression and clinical outcome of R-CHOP treated DLBCL
30,50,51]. Recent work demonstrated, that low expression of miR-
29-5p in DLBCL patients correlates with a signiﬁcantly worse
rognosis then DLBCL patients with high miR-129-5p levels [128].
lthough further clinical studies are necessary to corroborate the
rognostic impact of individual miRNAs in DLBCL, it is becoming
uite apparent that miRNA proﬁling will help in identiﬁcation of a
ubgroup of candidate patients for individualized therapeutic regi-
ens.
. Concluding remarks
In  the last few years, multiple publications have addressed the
eregulation of miRNAs in many types of cancer, including DLBCL.
t has become evident that an aberrant expression of these small
NAs is one of the crucial steps in the pathogenesis of lymphomas.
ecently, an increasing number of miRNAs have been incorpo-
ated into models for distinguishing different types of DLBCL while
redicting therapeutic response or survival outcome. However,
he precise mechanisms governing miRNAs expression and their
mpact on targeted genes/gene pathways are still being elucidated.
urthermore, much more work is needed in order to understand
he mechanisms and role of these small RNAs in lymphomagen-
sis as well as to determine their potential as biomarkers and/or
herapeutic targets. The recently described serum circulating miR-
As hold potential as a noninvasive biomarker for the diagnosis
f DLBCL. The question of whether miRNA-based therapy in B-cell
alignancies is ultimately clinically feasible is both a promising
nd challenging area of intense research.
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